Arş. Gör. FATİH KUŞ

1. Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study

Tunbekici S., Sahin G., Yuksel H. C., Acar C., Akın I., Aslanhan H., et al.

International Journal of Cancer , cilt.158, sa.6, ss.1703-1712, 2026 (SCI-Expanded, Scopus)

2. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

Efil S. C., Kus F., Koylu B., Durukan B. M., Bayram S., Guzel H. G., et al.

Cancers , cilt.18, sa.1, 2026 (SCI-Expanded, Scopus)

3. TMC6/8-associated epidermodysplasia verruciformis: germline variants and a complex structural alteration in a skin cancer predisposition syndrome

DURMAZ ÖZDİNÇ C. D., Güleray Lafcı N., ERKAN KOLAÇ D. D., AKÇİN Ö. Ç., Bulut N., Kuş F., et al.

European Journal of Human Genetics , 2026 (SCI-Expanded, Scopus)

4. Artificial Intelligence (ChatGPT-4o) in Adjuvant Treatment Decision-Making for Stage II Colon Cancer: A Comparative Analysis with Clinician Recommendations and NCCN/ESMO Guidelines

KUŞ F., Chalabiyev E., YILDIRIM H. Ç., Koc Kus I., ŞİRVAN F., DİZDAR Ö., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.35, sa.1, ss.68-74, 2025 (SCI-Expanded, Scopus, TRDizin)

5. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

Topal A., Akdag G., Yildirim S., Kinikoglu O., Isik D., Yildirim G., et al.

MEDICINA-LITHUANIA , sa.3, 2025 (SCI-Expanded, Scopus)

6. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.

JOURNAL OF CLINICAL MEDICINE , sa.6, 2025 (SCI-Expanded, Scopus)

7. Dynamine 3 as a diagnostic and prognostic biomarker in pancreatic cancer: Implications for early detection and targeted therapy

Yay F., Yildirim H. c., KUŞ F., YALÇIN Ş.

BIOMARKERS , sa.2, ss.147-166, 2025 (SCI-Expanded, Scopus)

8. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study

TÜNBEKİCİ S., YÜKSEL H. Ç., ACAR C., Sahin G., Orman S., Majidova N., et al.

CANCERS , cilt.17, sa.1, 2025 (SCI-Expanded, Scopus)

9. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

Degerli E., Arslan C., Selcukbiricik F., Olmez O. F., Erdem D., Hamdard J., et al.

MEDICINA-LITHUANIA , cilt.60, sa.12, 2024 (SCI-Expanded, Scopus)

10. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.

MEDICINE , cilt.103, sa.30, 2024 (SCI-Expanded, Scopus)

11. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.

International Journal of Clinical Oncology , cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)

12. Sirolimus experience in adult patients with vascular malformations

AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.

Vascular , 2024 (SCI-Expanded, Scopus)

13. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.

INTEGRATIVE CANCER THERAPIES , cilt.23, 2024 (SCI-Expanded, Scopus)

14. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.

Journal of Immunotherapy and Precision Oncology , cilt.6, sa.4, ss.170-176, 2023 (Scopus)

15. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.

Medicine (United States) , cilt.102, sa.18, 2023 (SCI-Expanded, Scopus)

16. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer

KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.

Biomarkers in Medicine , cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)

17. Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey

Kus C., Kus M. M., Keten H. S., Ucer H., Guvenc N., KUŞ F., et al.

Children , cilt.10, sa.2, 2023 (SCI-Expanded, Scopus)

18. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)

19. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.

Journal of Oncological Science , cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin)

21. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.

Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)